Treatment of hormone refractory prostate cancer requires new treatment strategies. Genetic prodrug activation therapy (GPAT) may provide a new therapeutic avenue. In this study the antitumour efficacy of the gene encoding herpes simplex virus thymidine kinase (HSVtk) activating the prodrug ganciclovir (GCV) was compared in two models of ectopic (subcutaneous) rat prostate cancer. Both models, which differ in their characteristics, were previously shown to be weakly immunogenic but susceptible to immunotherapy. Tumour cell lines were stably transfected with HSVtk and were rendered highly sensitive to GCV. Little or no bystander killing effect was observed by tk-transfected cells on wild-type cells in vitro. However, a significant in vivo bystander effect was observed suggesting an immune-mediated response. Indeed, such an immune response was capable of slowing the growth of distant wild-type tumours and increased overall animal survival. A T helper 1 immune response was generated as a result of GCV activation and cell kill, demonstrated by the secretion of IFN␥ by cultured splenocytes in response to tumour cells.
Introduction
Hormone refractory prostate cancer currently has a poor prognosis, as once a patient has progressed to this stage no treatment has been shown to alter overall survival. Increased testing of serum prostate-specific antigen (PSA) allows for earlier diagnosis of malignancy but curative success of radical prostatectomy or radiotherapy is limited to less than two-thirds of patients. Moreover, metastatic disease can be treated with anti-androgen therapy but overall survival from the time of diagnosis is between 2 and 3 years. In 1996, within the UK, 9700 men died from prostate cancer (Office of National Statistics, 1997; www.statistics.gov.uk). There is therefore a demand for novel therapies which may potentially impact upon hormone refractory disease. Among the many treatment BrDU staining of tk-transfected cells treated with GCV in vitro suggested apoptotic cell death, but Annexin V staining was less marked for one of the cell lines. Serial in vivo monitoring by non-invasive magnetic resonance spectroscopy (MRS) of the tk-transfected MATLyLu tumours demonstrated a decreased ATP/Pi ratio (a measure of cell energy status) during growth and an increase in the ATP/Pi ratio during regression initiated by treatment with GCV. Further, significant differences were found in the phosphomonester (PME) to total phosphate (⌺P) ratios in treated compared with untreated tumours, a result rarely seen in animal models, but commonly observed in patients. This study showed that a Th1-biased immune response generated by killing prostate tumour cells with tk/GCV can kill distant as well as local wild-type tumour cells. These findings suggest that GPAT may have a potential application in patients with both confined and metastatic prostate cancer and MRS may provide a method of monitoring response to treatment. Gene Therapy (2001) 8, 557-567.
strategies currently being considered, gene therapy appears to have potential to make an impact on prostate cancer. 1 The area of cancer gene therapy overlaps considerably with immunotherapy in that many of the gene transfer strategies involve transduction with genes encoding directly or indirectly immunostimulatory molecules. Genes can be transferred either directly in situ (in vivo) or to isolated tumour cells (ex vivo) which are then irradiated and returned to the patient as a 'cancer vaccine'. 2 Since prostate cancer cells express specific antigens, this cancer appears to be a potential target for immune responses. Early clinical trials using whole tumour cells transduced with granulocyte-macrophage colony-stimulating factor (GM-CSF), 3 or dendritic cells pulsed with prostate-antigen peptides 4 resulted in patients demonstrating tumour-specific immune responses. This suggests that prostate cancer may be amenable to immune-based therapy even though clinical responses in these trials were limited due to the advanced stage of disease in the patients. In addition, the presence of tumour-infiltrating lymphocytes (TIL) within prostate tumours has been correlated with a better prognosis, 5 further suggesting the role for immune manipulation as a treatment strategy. Even nonspecific immunotherapy with M. vaccae has been shown to have potential antitumour activity. 6 This may be countering the suppression of cell-mediated immunity which occurs in many malignancies such as melanoma, 7 colorectal cancer, 8 as well as prostate cancer. It is known that many patients undergoing radical prostatectomy are left with minimal residual disease and thus may be in a situation where gene therapy/immunotherapy has good efficacy against the small residual tumour burden. However, there are specific characteristics of prostate cancer that may result in immune evasion, such as loss of expression of MHC class I molecules, 9 disruption of other antigenpresenting machinery, and the expression of immunosuppressive molecules such as TGF␤, IL-10 and Fas ligand.
Genetic prodrug activation therapy (GPAT) is an innovative approach that can kill tumour cells by inserting 'suicide' genes into cancer cells, a strategy also referred to as suicide gene therapy. The most frequently described GPAT strategy is the herpes simplex virus thymidine kinase (HSVtk) enzyme/ganciclovir (GCV) prodrug system. HSVtk phosphorylates GCV and this product incorporates into DNA during cell division, thus killing the cell. HSVtk/GCV is a potential avenue for treating cancer by the direct transduction and killing of a proportion of tumour cells in vivo and by the associated local bystander killing effect. 10 In addition, the immune responses generated by this process are important for the local bystander effect and may also affect distant metastases. 11, 12 GPAT using the HSVtk system has already entered clinical trials for ovarian cancer 13 and mesothelioma 14 using adenoviral delivery of HSVtk. In particular, a recent trial of HSVtk/GCV for organ-confined prostate cancer post-irradiation has shown some evidence of antitumour activity using a falling serum PSA as a surrogate marker of response. 15 However, methods for direct monitoring of a therapeutic effect are needed, especially if tumours no longer secrete PSA.
Modelling prostate cancer in animals is required in pre-clinical 'proof-of-principle' studies and here we describe two rat models of prostate cancer which show some characteristics of the human disease. We show that the magnitude of the bystander effect associated with HSVtk/GCV is more significant in vivo than in vitro and that the associated immunity that is elicited in vivo can effect responses in distant tumours that represent metastases. 16 Magnetic resonance spectroscopy (MRS) has the unique ability to measure the concentrations of chemicals in living tissue noninvasively. 17 The proteins expressed as a result of gene transfection may alter the concentration of cellular metabolites, thus the measurement of tumour biochemistry by MRS may represent an excellent method for monitoring GPAT strategies for cancer. Since the first in vivo MR spectra were acquired in tumours in rats 18 and then in patients, 19 
Results
In vitro characteristics of cells Following retroviral transfection of the tumour cells, neomycin-resistant clones were picked, replated and propagated. Clones that showed the greatest susceptibility to killing with GCV were selected for further study. These clones were totally eradicated with 5 g/ml GCV, whilst the growth of the wild-type cells was not affected at this concentration. The increase in sensitivity to GCV of the tk-transfected clones was compared to wild-type cells over a wide range of GCV concentrations (0.001 to 100 g/ml) ( Figure 1 a and b) . Thus the LC 50 of MLL was decreased from 9 to 0.006 g/ml whilst the LC 50 of PAIII was decreased from 20 to 0.08 g/ml by tk-transfection.
In order to test for a possible bystander killing effect, wild-type (WT) and tk-transfected (tk) tumour cells were mixed in the following proportions; 100% WT/0% tk, 90% WT/10% tk, 70% WT/30% tk, 50% WT/50% tk, 30% WT/70% tk, 10% WT/90% tk, 0% WT/100% tk, and treated with 5 g/ml GCV. At either time point of 5 or 7 days no significant in vitro bystander effect was observed for either MLL or PAIII cell lines (Figure 2 a  and b) . Indeed, the rapid growth of MLL was very evident in these experiments where the cells simply expanded to fill the culture wells.
In vivo experiments
The in vivo growth of the tk-transfected tumour line was found to be slightly retarded compared to the wild-type line (Figure 3a ) in the MLL model. This difference was not found to be statistically significant (P = 0.09). In the PAIII model the growth rates of wild-type and tk-transfected tumours were very similar (Figure 3b) . In order to test the in vivo sensitivity of the tumours to GCV, an inoculum of 1 × 10 5 MLL tumour cells and 1 × 10 6 PAIII tumour cells was injected subcutaneously into syngeneic rats. After tumours had reached 5 mm in diameter the rats were given GCV i.p. daily for 5 days at the following doses: 10, 50 and 100 mg/kg. All these doses eradicated the tk tumours entirely (Figure 3c and d) . Animals in which the tumours had receded were monitored further. In three out of eight of the Cops and four out of eight of the Lobs that had received 10 mg/kg of GCV the tumours grew back. This was not evident in the animals receiving higher doses of GCV. In addition, the weight of the animals during treatment with the various doses of GCV was monitored. Animals receiving 100 mg/kg showed the largest fluctuation in weight with an average weight loss of 20% body weight during the 5 day treatment course. Thus the dose of 50 mg/kg was deemed to be the optimal dose in terms of efficacy and toxicity.
In view of the lack of demonstrated bystander killing in vitro, an in vivo bystander effect was examined. Mix- tures of wild-type and tk-transfected lines in the following proportions; 100% WT/0% tk, 75% WT/25% tk, 50% WT/50% tk, 25% WT/75% tk, 0% WT/100% tk, were injected subcutaneously as in previous experiments, allowed to grow to 5 mm and then treated with 50 mg/kg GCV i.p. Significant bystander effect occurred in vivo. At day 20, 25% Mtk resulted in a 77.6% reduction in tumour size over wild-type alone (P = 0.007) and at day 26, 50% Ptk caused a 57.9% reduction in their size (P = 0.03) (Figure 4a and b). Since there was no in vitro bystander effect observed this suggested that there was an immune component to this effect. Rats that had completely rejected their initial tumours were rechallenged Gene Therapy a b with wild-type cells, a significant delay in tumour development was observed with 12.5% of Cops and 50% of Lobs totally protected at 28 days and 55 days, respectively, after rechallenge (Figure 4c and d) .
Figure 2 In vitro bystander effect. Wild-type (WT) and tk-transfected (tk) MLL (a) or PAIII (b) tumour cells were mixed in the following
We next investigated whether tk-killing could have an effect on established wild-type tumours injected and grown at a site distant from the site where tk-transfected tumours were established in the same animal. Tumours were grown bilaterally on the opposite flanks of the animals with two groups of animals receiving tk-transfected tumours on the left thigh and wild-type tumours on the right, a final group received bilateral wild-type tumours. Wild-type tumours grew at a normal rate when they were grown on both flanks of the rats with or without GCV treatment (Figure 5a and b) . Growth of tk-transfected tumours was abrogated by GCV and this killing also significantly slowed the growth of wild-type tumours on the opposite flank. This effect on wild-type tumours was associated with a significant increase in survival compared with the animals with bilateral wild-type tumours treated with GCV and also the animals with tktransfected and wild-type tumours treated with PBS (MLL/Mtk, P = 0.002; PAIII/Ptk, P = 0.004).
PAIII/Ptk tumour cells was injected subcutaneously into the shaven thigh of Cop or Lob rats respectively (n = 8 per group). The growth of the Mtk tumour line was found to be slightly retarded compared with the wild-type line (a). This difference was not statistically significant (P = 0.09). Growth rates of wild-type and Ptk tumours were very similar (b).

Immune responses
In order to investigate the nature of the anti-tumour immune responses following tk/GCV killing of tumour cells, spleens were taken from rats with established tktransfected tumours treated with GCV and compared with a group of rats that received no GCV. Single cell lymphocyte suspensions were prepared and incubated for 5 days with tumour cells. After this time the lymphocytes were harvested and tested for CTL activity against the syngeneic cell line whilst the supernatants from splenic cultures were tested for secreted cytokines, IFN␥ and IL-4 by ELISA. On average, higher levels of IFN␥ were detected in the group whose Mtk tumours had received GCV treatment compared with those not receiving GCV and naïve controls (Table 1) . However, no CTL activity was detectable with the Cop/Mtk system. In the Lob/Ptk system low levels of CTL activity were detected in the GCV-treated group, which were significantly higher than those of the naïve rats (Figure 6a ). Tk-transfected tumours were removed from dead rats after GCV treatment or PBS treatment, disaggregated, and stained for FACS analysis. All the tumours appeared to have an infiltration of CD45 + leukocytes (data not shown). Tk/GCV tumour cell killing was associated with higher CD8 + infiltration, whilst equivalent CD4 + and NK infiltration was observed in both groups.
Apoptosis
A recent report has demonstrated that the mechanism of tumour cell death with tk/GCV may affect immuno- genicity. 26 To investigate this, Mtk and Ptk cells were treated with 5 g/ml GCV and then analysed by BrDU and Annexin V staining by FACS (Figure 7 ). Both Mtk and Ptk showed Ͼ70% BrDU staining following GCV treatment. However, while Ptk showed considerable Annexin V staining (66%) following GCV, Mtk showed only 19.9%. In order to follow up these findings in terms of 'danger signal' generation, RNA was extracted from GCV-treated and untreated cells. The RNA was reversetranscribed and PCR was carried out to look for inducible rat hsp70 expression. No product was found in GCVtreated compared with heated (42°C) cells that expressed abundant hsp70 (data not shown).
Magnetic resonance imaging and spectroscopy Serial 31 P MR spectra from a representative Mtk tumour treated with GCV are shown in Figure 8a . Likewise Figure 8b shows images of a typical Mtk tumour shrinking and becoming walled off from the animal during treatment with GCV. Because of the inherent lack of sensitivity and relatively poor signal/noise of in vivo 31 P MRS techniques only tumours treated with 0 and 100 mg doses of GCV were monitored where there was the best chance of seeing significant differences. The tumours were monitored by MRS for 5 days starting on the 10th day after inoculation. After 3 days of treatment, a significant difference (P Ͻ 0.05) was evident in the ratio of the ␤-ATP peak to the inorganic phosphate (Pi) peak (␤-ATP/Pi) between tumours that had received daily GCV treatment and untreated controls. After 4 days of treatment, this difference was still significant (P Ͻ 0.01) and in addition, a significant difference (P Ͻ 0.01) was also seen in the ratio of the phosphomonoester (PME) peaks to the total phosphate value (PME/⌺P) (Figure 8c ).
a b
Figure 7 Apoptosis of tumour cells following tk/GCV treatment. Apoptosis of tumour cells was assayed by both BrDU staining (a) and by Annexin V staining (b). No GCV is in red whilst GCV is in white. Figures indicate percentage of positively stained cells (within M1 marker) without GCV/with GCV.
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Discussion
The direct killing effect of HSVtk/GCV on tumours is itself highly desirable. However, current vector technology may not allow sufficient numbers of cells to be transduced with HSVtk to allow the eradication of an entire tumour upon exposure to GCV. A bystander effect causes the death of untransduced tumour cells locally by transfer of metabolites and by the generation of an immune response. This immune response may also have an impact on tumour cells that have metastasised. Indeed, even if this approach only manages to slow tumour growth, the prospect of improved palliation cannot be ignored. The aim of this study was to establish a model of GPAT for prostate cancer that could provide valuable information about the activation system, how it functions and how various effects can be monitored. The demonstration of systemic anti-tumour immunity by a distant bystander effect has important clinical implications. Two rat prostate tumour models were used since they show different characteristics from each other that may mirror human disease. PAIII in the Lobund-Wistar rats is a slow-growing tumour that may be more akin to early human disease. MLL in the Copenhagen rats, the Dunning model of prostate cancer, on the other hand is a fast-growing, aggressive tumour that may have some resemblance to hormone refractory disease. In terms of immunogenicity we had previously demonstrated that the two cell lines showed moderate immune protection when combined in whole cell vaccines with a mycobacterial adjutant. 27 More recently we have shown cross-reactivity between the lines when MLL was used as an allogeneic vaccine without adjuvant for protection against PAIII in 1 31 
H images acquired from each tumour. Images showed GCV-treated Mtk tumours rapidly regressing and becoming walled off from the animal. (c) Serial in vivo 31 P MRS measurements of ATP/P i and PME/⌺P ratios. An inoculum of 1 × 10 6 Mtk tumour cells was injected subcutaneously into the shaven thigh of Cop rats. Rats were treated with GCV i.p. daily for 5 days at 100 mg/kg (n = 6) or saline (n = 8). Serial in vivo
P MR measurements were made on each tumour and the ATP/P i and PME/⌺P ratios determined. Tumours in GCV-treated rats displayed an increase in ATP/P i and decrease in PME/⌺P concomitant with treatment. Untreated tumour growth correlated with a marked decrease in ATP/P i and no change in PME/⌺P. Points marked with an asterisk on each graph were significantly different from each other (P Ͻ 0.05, n = 5 or 6). ⌺P was calculated from each spectrum as the sum of the areas under all metabolite peaks in the spectrum.
Lobund-Wistar rats. 28 Other groups have also shown that MLL vaccines expressing IL-2 29 or GM-CSF 30 generated immune protection. Thus the tumour models are susceptible to immune-based therapy. Transfection of HSVtk into both tumour lines imparted GCV sensitivity which caused their eradication in vitro and in vivo. Interestingly, no significant bystander effect on wild-type cells was observed in vitro. This contrasts to previous studies of killing of prostate tumour cells where a murine tumour cell line and a human cell line (DU-145) did show in vitro bystander killing after transduction. However, a further human cell line (PC3) failed to show significant bystander effect using the same GPAT system. 31 A significant local bystander effect was observed in vivo, suggesting an immune basis for tumour destruction. Animals that were rechallenged with wild-type cells, following previous eradication of tk-transfected tumours by GCV, showed significant delay in tumour growth and several animals were completely protected.
The effect of tk killing on established wild-type tumours distant from the tk-transfected tumour was particularly significant. Distant, non-contiguous wildtype tumours represent metastases similar to those occurring in prostate cancer patients.
There was a significant reduction in tumour volume and increased survival of animals as a result of the tkkilling. This study has shown that an anti-tumour immune response can be raised after tk/GCV treatment and that this may be beneficial to survival against metastatic disease.
The nature of the immune response was examined. The secretion of IFN␥ by splenocytes and CTL activity in vitro, and CD8
+ cell infiltration of tumours in vivo was in keeping with a cell-mediated Th1 response, which is similar to previous observations in mouse tumour models. 32 Recent evidence has suggested that the mechanism by which tumour cells die (apoptosis versus necrosis) with tk/GCV may influence the immune response generated. 26 Indeed, necrosis was considered more immunogenic than apoptosis, which is the 'physiological' way in which cells die. Using BrDU staining both cell lines appeared to die by apoptosis rather than necrosis. Annexin V staining, a marker of early apoptosis, suggested that apoptosis occurred to a greater extent with Ptk than Mtk. Expression of the 'danger signal' hsp 70, which was previously expressed in a mouse tumour model in association with necrosis was not found in either GCV-treated cell line. This does not exclude the expression of other danger signals but suggests apoptosis is the dominant mode of cell death and facilitated 'immune priming'. Immune priming with HSVtk/GCV has been further improved in other studies by cotransfection of the tumour cells with tk and cytokine genes. 33 Potential improvement in therapy could be effected by combination with whole tumour cell vaccination. 27 Indeed the tumours treated with 10 g/kg of GCV that eventually regrew may be due to the need to induce a strong priming immune response which our results suggest may be dose-related, hence further priming using such contributions as cytokines may further enhance effective antitumour immunity.
In a previous in vivo 31 P MRS study, Stegman et al 24 showed that treatment of tk transfected C6 gliomas with GCV did not significantly change the in vivo ATP/Pi ratio or PME levels from pretreatment values. In contrast, our
Gene Therapy study shows that GCV treatment in our tumour model (tk-transfected MLL tumours) causes significant changes in tumour ATP/Pi and in PME/⌺P. Thus, in this model, effects of GCV therapy of tk-transfected tumours can be monitored by 31 P MRS. Further, we have shown that the changes concomitant with treatment and tumour regression are similar to those seen in other treatments, such as chemotherapy or radiotherapy. These changes include an increase in the high energy phosphate metabolites following treatment. 20, 34 and a decrease in untreated tumour growth. In MR studies on the distant bystander effect (which is the subject of another paper) similar spectra and responses were obtained in the untreated and treated transfected tumours as in this study, whereas the distant wild-type tumour, whose growth rate was significantly decreased by GCV treatment, showed no change in the ATP/Pi ratio.
A number of mechanisms to explain these findings have been put forward 34, 35 that related to the vascularity and oxygenation of the responding, regressing tumour.
The fall in PME/⌺P seen in this model has rarely been seen in animal tumour models, but it is the most common effect observed in human tumours in patients. A metaanalysis by Negendank et al 36 who reviewed 61 patients receiving chemo-or radiotherapy found that 38/47 of those whose PME signal decreased eventually responded to treatment. In contrast, only 1/14 nonresponders showed a PME decrease. PMEs are synthesized by the enzymatic activity of ethanolamine and choline kinases which catalyze the first step of phospholipid biosynthesis in vivo. An increase in the PME peaks is thought to be associated with an increase in cell membrane synthesis. 37 This investigation did not address the actual process of transfer of the tk genes to the tumours in vivo. Adenoviral vectors are currently the vehicles of choice for such transduction in animal models 31 and in early human trials of prostate cancer 15 , where delivery directly into the prostate is feasible. This next step is the subject of current investigation in our laboratory.
This study has a number of implications for using such a GPAT approach in the clinic. The finding that the immune response generated by HSVtk/GCV-killing of tumour cells in vivo causes local and distal tumour regression is pivotal to the value of this approach. Reliable monitoring of the effects of this process is vital and studies by MRI and MRS both at the site of primary treatment and at distal, nontransfected tumours are ongoing and will be reported separately. Immune responses could also be monitored following treatment both with systemic lymphocytes and histologically within tumours. These findings are encouraging for embarking on more comprehensive clinical trials of GPAT in prostate cancer.
Materials and methods
Animals
Pathogen-free 12-week-old male Copenhagen rats (Cops) were obtained from B&K (Hull, UK) and 12-week-old male Lobund-Wistar rats (Lobs) were obtained from Harlan (USA). All procedures were carried out under mild anaesthesia and in accordance with the UK Home Office and ethical guidelines.
Cell lines
The MAT-LyLu (MLL) subline of the Dunning rat prostate cancer was obtained from ECACC and was cultured in RPMI 1640 (Sigma, Poole, UK), 10% heat inactivated foetal calf serum (Sigma), 2 mm glutamine (Sigma), penicillin 100 g/ml (Life Technologies, Paisley, UK) and streptomycin 100 g/ml (Life Technologies) in 5% CO 2 . The PAIII rat prostate cancer cell line was kindly provided by Dr Morris Pollard (Lobund Laboratory, Indiana, USA) and was cultured in DMEM (Sigma), 10% heat inactivated foetal calf serum (Sigma), 2 mm glutamine (Sigma), penicillin 100 g/ml, streptomycin 100 g/ml, in 5% CO 2 . The cells were passaged with 0.05% trypsin and 0.02% EDTA (Sigma) and were free from mycoplasma as assessed by the gene probe method (GenProbe, San Diego, CA, USA).
Transfection and in vitro studies
The gene encoding HSVtk was cloned into pBabeNeo and this construct was transfected into the AM12 retroviral packaging cell line, as described previously. 11 This packaging cell line was kindly provided by Dr R Vile (Mayo Clinic, Rochester, MN, USA). Viral supernatant harvested from these cells was used to transfect the rat prostate tumour lines in the presence of 4 g/ml polybrene. Clones were grown in neomicin (G418) (150 g/ml for MLL and 500 g/ml for PAIII) and then tested for their sensitivity to killing by GCV (Cymevene, Roche) at a range of concentrations compared to wild-type cells. Tktransfectants of MLL and PAIII were referred to as Mtk and Ptk, respectively. In vitro growth characteristics of the transfected cell lines were carried out in 24-well plates (Falcon, Becton-Dickinson). Bystander effect was investigated by mixing wild-type and tk-transfected cells in various proportions followed by GCV treatment. Proportions of surviving cells were assessed by a standard MTT assay, read on a spectrometer at optical density 550 nm.
Tumour growth in vivo
The tumour cells were prepared for tumour challenge by detachment with trypsin/EDTA, washed three times in PBS and resuspended at the specified density in PBS. Prostatic tumours were induced ectopically by the injection of 1 × 10 6 PAIII cells in 100 l PBS subcutaneously into the shaven thigh of each Lobund-Wistar rat. In the case of Copenhagen rats the tumorigenic dose of MLL cells was 1 × 10 5 cells, as optimised previously. 27 Tumour growth was assessed every 2-3 days using microcalipers to measure perpendicular diameters. To eradicate the tktransfected tumours, escalating GCV doses (10, 50 and 100 mg/kg) were administered in 100 l of PBS intraperitoneally. Bystander effect was investigated by mixing tktransfected and wild-type cells in various proportions before inoculation, followed by GCV treatment. Rats were killed when the tumour reached 25 mm in one of the diameters or when ulceration or bleeding occurred. Tumour volumes were calculated using the standard formula Immune responses Spleens were taken from dead rats that had previously had tumours with or without GCV treatment. The spleens were passed through 100 m filters to obtain a single-cell suspension and then red blood cells were lysed with 0.87% ammonium chloride. The cells were washed and resuspended in RPMI 1640 supplemented with foetal calf serum/glutamine/penicillin/ streptomycin as above plus 50 m 2-mercaptoethanol and 10 U/ml human rIL-2 (recombinant IL-2). Cells at 1 × 10 6 /ml were cultured with irradiated (50 Gy) tumour cells at a ratio of 50 lymphocytes to one tumour cell. After 5 days of incubation cells were harvested supernatants were collected and tested for cytokines (IFN␥ and IL-4) using ELISA kits from PharMingen, following the manufacturer's instructions. A standard cytotoxic T cell (CTL) assay was carried out by 51 Cr release from labelled tumour cells and various effector (CTL) to target (tumour cells) ratios. To investigate infiltration of tumours by leukocytes, tumours were excised and passed through 100 m filters (Falcon) to obtain a single cell suspension and then stained with antibodies for CD45, CD4, CD8, and CD56 (from Pharmingen) followed by FITC-labelled secondary antibody. Cells were analysed on a FACScan (Becton-Dickinson) with 10 000 events collected per sample.
Apoptosis
Tumour cells with or without the tk gene were cultured with 5 g/ml GCV and then detached as above. Any floating cells were pooled together with cells detached from plates with trypsin/EDTA. Cells were assayed for apoptosis using an APO-BrDU kit (Pharmingen) following the manufacturer's instructions. Briefly, the cells were fixed in 1% paraformaldehyde, washed, and then stored in 70% ethanol at −20°C until assayed. The cells were washed in PBS, resuspended in 50 l of DNA labelling solution containing 10 l reaction buffer, 0.75 l TdT enzyme, 8.0 l BrDUTP and 32.25 l distilled water. The cells were incubated for 60 min at 37°C. The cells were stained with anti-BrDU antibody and then counterstained with propidium iodide shortly before running on a FACScan. 10 000 events were collected per sample.
Magnetic resonance spectroscopy Animals were placed in the bore of a Varian 200-300 spectrometer at 4.7T with the tumour resting on a 10 mm dual-turn 31 P surface coil. 31 P MR spectra were acquired using image-guided localised spectroscopy by the ISIS (Image Selected In vivo Spectroscopy) technique 38 with adiabatic pulses, 1024 scans, a spectral width of 5000 Hz and a repetition time of 3 s. A voxel for localised 31 P spectroscopy was prescribed from a 1 H scout image avoiding animal body wall where this was evident in the image. 10 Hz line-broadening was applied before Fourier transform. The position of the coil was marked on each tumour with indelible ink following the first experiment session to ensure the same tumour position for subsequent experiments. Spectra were analysed using VAR-PRO, a variable projection time-domain non-linear least squares fitting algorithm, 39 implemented using Matlab version 5.1 (The Mathworks Inc., MA, USA). The relative peak areas of visible 31 P-containing metabolites were determined for each spectrum and various ratios are reported. Total phosphate (⌺P) for each spectrum was calculated as the sum of the areas of all the 31 P-containing peaks in that spectrum.
Statistics
Mean tumour volumes were compared between groups using the Student's t test. Survival between groups was analysed by the log-rank test.
